Skip to content

Study on the Mechanism of Yiqi Zengmian Fang and Huashibaidu Granules on New Coronary Pneumonia

Study on the Mechanism of Yiqi Zengmian Fang and Huashibaidu Granules on New Coronary Pneumonia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050483
Enrollment
Unknown
Registered
2021-08-28
Start date
2021-08-25
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-59 years; 2. Consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to any component of the vaccine, or who have experienced severe allergic reaction to the vaccine in the past, such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioedema or abdominal pain; 2. Those who are allergic to the ingredients in Yiqi Zengmai Formula; 3. Subjects with fever, acute disease, severe chronic disease, or acute onset of chronic disease; 4. Pregnant subjects and lactating subjects, have a birth plan within 3 months of vaccination; 5. Those with a history or family history of convulsions, epilepsy, encephalopathy or mental illness; those with uncontrolled epilepsy and other progressive neurological diseases, those with a history of Guillain-Barre syndrome; 6. Has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; 7. Known or suspected to suffer from severe respiratory disease, severe cardiovascular disease, liver and kidney disease, malignant tumor; 8. Those with a history of new coronavirus infection; 9. Taking drugs that may affect immune function, such as immunosuppressants or immune enhancers or glucocorticoids (>=10mg prednisone or other equivalent glucocorticoids) within or within one month before enrollment; 10. Those who are considered inappropriate by researchers or vaccination doctors to be vaccinated against the new crown inactivated vaccine.

Design outcomes

Primary

MeasureTime frame
Coronavirus disease RBD specific antibody levels;

Countries

China

Contacts

Public ContactCheng Zujue

The Second Affiliated Hospital of Nanchang University

juejue@126.com+86 13870876167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026